Barclays PLC Has $116,000 Stock Position in Gyre Therapeutics, Inc. (NASDAQ:GYRE)

Barclays PLC lifted its holdings in shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) by 281.8% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 9,288 shares of the company’s stock after buying an additional 6,855 shares during the period. Barclays PLC’s holdings in Gyre Therapeutics were worth $116,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. FMR LLC acquired a new position in shares of Gyre Therapeutics during the 3rd quarter worth $47,000. Rhumbline Advisers acquired a new position in shares of Gyre Therapeutics during the 2nd quarter worth $123,000. Renaissance Technologies LLC acquired a new position in Gyre Therapeutics in the 2nd quarter worth about $166,000. Bank of New York Mellon Corp acquired a new position in Gyre Therapeutics in the 2nd quarter worth about $218,000. Finally, WINTON GROUP Ltd acquired a new position in Gyre Therapeutics in the 2nd quarter worth about $220,000. Institutional investors and hedge funds own 23.99% of the company’s stock.

Insiders Place Their Bets

In other Gyre Therapeutics news, President Songjiang Ma sold 2,000 shares of the company’s stock in a transaction dated Thursday, December 26th. The stock was sold at an average price of $12.70, for a total value of $25,400.00. Following the completion of the transaction, the president now owns 2,928,467 shares of the company’s stock, valued at $37,191,530.90. This represents a 0.07 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders sold a total of 12,941 shares of company stock valued at $153,041 in the last 90 days. Corporate insiders own 19.52% of the company’s stock.

Gyre Therapeutics Stock Down 3.7 %

Shares of GYRE opened at $9.62 on Thursday. Gyre Therapeutics, Inc. has a 12-month low of $8.26 and a 12-month high of $27.10. The business has a 50-day simple moving average of $12.20 and a two-hundred day simple moving average of $12.65.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.